146 related articles for article (PubMed ID: 35305393)
1. SARS-CoV-2 triggered relapse of multiple sclerosis.
Finsterer J
Clin Neurol Neurosurg; 2022 Apr; 215():107210. PubMed ID: 35305393
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
[TBL] [Abstract][Full Text] [Related]
3. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
Etemadifar M; Sigari AA; Sedaghat N; Salari M; Nouri H
Hum Vaccin Immunother; 2021 Oct; 17(10):3481-3483. PubMed ID: 34015240
[TBL] [Abstract][Full Text] [Related]
4. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
[TBL] [Abstract][Full Text] [Related]
5. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
Conte WL
Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
[TBL] [Abstract][Full Text] [Related]
6. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
Etemadifar M; Sedaghat N; Aghababaee A; Kargaran PK; Maracy MR; Ganjalikhani-Hakemi M; Rayani M; Abhari AP; Khorvash R; Salari M; Nouri H
Mult Scler Relat Disord; 2021 Jun; 51():102915. PubMed ID: 33799284
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
10. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.
Pugliatti M; Hartung HP; Oreja-Guevara C; Pozzilli C; Airas L; Alkhawajah M; Grigoriadis N; Magyari M; Van Wijmeersch B; Zakaria M; Linker R; Chan A; Vermersch P; Berger T
Front Immunol; 2022; 13():1045101. PubMed ID: 36325318
[TBL] [Abstract][Full Text] [Related]
11. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
[TBL] [Abstract][Full Text] [Related]
12. Case report: A novel case of COVID-19 triggered tumefactive demyelinating lesions in one multiple sclerosis patient.
Hu J; Huang L; Qiu Z; Liu Y; Shen K; Tang B; Qian J
Front Neurosci; 2023; 17():1287480. PubMed ID: 38075268
[TBL] [Abstract][Full Text] [Related]
13. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
Barzegar M; Vaheb S; Mirmosayyeb O; Afshari-Safavi A; Nehzat N; Shaygannejad V
Mult Scler Relat Disord; 2021 Jul; 52():102947. PubMed ID: 33979771
[TBL] [Abstract][Full Text] [Related]
14. A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies.
Kataria S; Tandon M; Melnic V; Sriwastava S
eNeurologicalSci; 2020 Dec; 21():100287. PubMed ID: 33163634
[TBL] [Abstract][Full Text] [Related]
15. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E
Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878
[TBL] [Abstract][Full Text] [Related]
16. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
17. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
18. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
19. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
[TBL] [Abstract][Full Text] [Related]
20. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
